Amgen Inc. (NASDAQ:AMGN) Plans Quarterly Dividend of $2.52

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Wednesday, March 4th. Shareholders of record on Friday, May 15th will be given a dividend of 2.52 per share by the medical research company on Friday, June 5th. This represents a c) annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th.

Amgen has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a dividend payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 47.1%.

Amgen Price Performance

NASDAQ AMGN opened at $379.27 on Thursday. Amgen has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock’s 50-day moving average is $351.83 and its two-hundred day moving average is $321.58. The firm has a market cap of $204.45 billion, a P/E ratio of 26.65, a price-to-earnings-growth ratio of 3.74 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the business earned $5.31 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts anticipate that Amgen will post 20.62 earnings per share for the current fiscal year.

Institutional Trading of Amgen

Several institutional investors have recently made changes to their positions in the business. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its position in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in Amgen in the 4th quarter valued at $26,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the second quarter valued at $27,000. Finally, Evelyn Partners Investment Management LLP acquired a new position in Amgen during the second quarter worth $32,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.